DUPIXENT
Live / Registered — Registered — Section 8 accepted (as of 04 Nov 2023)
What this means for you
Registered since 04 Jul 2017. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87202613
- Registration number
- 5235634
- Mark type
- Design + words
- Filed
- 13 Oct 2016
- Published for opposition
- 18 Apr 2017
- Registered
- 04 Jul 2017
- Attorney of record
- Karen Lim
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of allergies and allergic diseases and disorders, autoimmune diseases and disorders, dermatological diseases and disorders, damaged skin and tissues, gastrointestinal diseases and disorders, inflammation and inflammatory diseases and disorders, respiratory diseases and disorders
Owner
- Sanofi Biotechnology, Paris, FR
- Sanofi Biotechnology, 75008 Paris, FR
- Sanofi Biotechnology, 75008 Paris, FR
Prosecution history
- 04 Nov 2023 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 04 Nov 2023 — REGISTERED - SEC. 8 (6-YR) ACCEPTED
- 04 Nov 2023 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 06 Jul 2023 — TEAS SECTION 8 RECEIVED
- 04 Jul 2022 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 08 Jan 2020 — REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
- 10 Dec 2019 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 04 Jul 2017 — REGISTERED-PRINCIPAL REGISTER
- 18 Apr 2017 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 18 Apr 2017 — PUBLISHED FOR OPPOSITION
- 05 Apr 2017 — REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
- 31 Jan 2017 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 29 Mar 2017 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 16 Mar 2017 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 10 Mar 2017 — APPROVED FOR PUB - PRINCIPAL REGISTER